{"id":18173,"date":"2026-06-09T18:01:00","date_gmt":"2026-06-09T16:01:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=d08c28ef55c21b4d4061c27fead45807"},"modified":"2026-06-09T18:01:00","modified_gmt":"2026-06-09T16:01:00","slug":"blue-matter-expands-capabilities-in-healthcare-policy-support-for-life-sciences-led-by-partner-milena-sullivan","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=18173","title":{"rendered":"Blue Matter Expands Capabilities in Healthcare Policy Support for Life Sciences Led by Partner, Milena Sullivan"},"content":{"rendered":"

NEW YORK--(BUSINESS WIRE)--Blue Matter today announced the launch of an expanded policy capability to support biopharma clients, led by Milena Sullivan, a Partner who joined the firm in December 2025.<\/p><\/a><\/a>

\nMilena Sullivan brings more than 20 years of experience in healthcare policy, advocacy, and market access, advising life science companies, trade associations, and provider organizations on policy issues shaping their business. Prior to joining Blue Matter, she spent almost a decade with Avalere Health, where most recently she led the policy practice. She has also held in-house policy roles at Bristol-Myers Squibb and Novartis Vaccines and Diagnostics, as well as policy positions in the nonprofit space, including at the Center for Strategic and International Studies (CSIS). She holds an MA in International Policy and Practice from The George Washington University and a BA from Miami University of Ohio.<\/p>

\nAt Blue Matter, Milena is leading a policy capability that integrates directly into the firm's broad range of client offerings, so clients get policy insight embedded in the strategic decisions where it matters most. According to Sullivan, \u201cThe nature of US health policy has shifted from discrete proposals to a coordinated recalibration of pressure points that collectively steer market behavior. Policy changes and political signaling are affecting nearly every aspect of commercial strategy in biopharma.\u201d She added, \u201cOur goal is to help clients cut through the uncertainty and transform confusion into competitive advantage.\u201d<\/p>

\nThe firm's policy offerings encompass the full arc of client need, from policy monitoring and analysis through strategy development, scenario planning, risk mitigation, and external engagement. Capabilities also include policy-informed commercial, access, evidence, and launch strategy development.<\/p>

\nManaging Partner, Ashwin Dandekar said, \u201cMilena and her team bring outstanding policy expertise to the team. Not only are they highly effective as dedicated policy experts, but they also shine as a \u2018force multiplier\u2019 that embeds across all our consulting teams, including commercial, market access, medical affairs, communications, and R&D. We\u2019re very excited about our expanded capabilities in this area.\u201d<\/p>

\nAbout Blue Matter<\/b><\/p>

\nBlue Matter (www.bluematterconsulting.com<\/a>) is a global commercialization partner serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves a broad spectrum of biopharmaceutical organizations, from top-20 global companies to emerging biotech firms. Blue Matter helps clients maximize value at the product, portfolio, and organization levels by providing market insights, strategic and operational consulting, and communications services.<\/p> Contacts<\/b>

\nCraig Dunkley\ncdunkley@bluematterconsulting.com<\/a>+1 (919) 539-0658<\/p>","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–Blue Matter today announced the launch of an expanded policy capability to support biopharma clients, led by Milena Sullivan, a Partner who joined the firm in December 2025.
\nMilena Sullivan brings more than 20 years of experi…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-18173","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18173"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18173\/revisions"}],"predecessor-version":[{"id":18174,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18173\/revisions\/18174"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}